11 completed. 11 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 11 |
| Phase 2 | 1 | Completed 1 |
Follow Thymoma: new trials by email Literature Review of Thymoma trials Research Report on Thymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S QBS10072S - Astrocytoma, Brain Cancer | Phase 1 | Completed | Quadriga Biosciences, Inc. | 15 | 2020-07-20 | 2023-01-18 |
| 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours 177Lu-DOTA-TATE + olaparib - Clinical Trial, Phase I, Neuroendocrine Tumors | Phase 1 | Completed | Vastra Gotaland Region | 18 | 2020-04-23 | 2026-04-14 |
| Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Bosutinib, Pemetrexed - Carcinoma, Non-Small-Cell Lung, Mesothelioma | Phase 1 | Completed | Nagla Abdel Karim | 6 | 2019-12-10 | 2022-06-14 |
| Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Vorolanib, Nivolumab - Thymic Carcinoma, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 88 | 2018-07-10 | 2024-10-08 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors XmAb20717 - Melanoma, Breast Carcinoma | Phase 1 | Completed | Xencor, Inc. | 150 | 2018-07-10 | 2022-12-01 |
| Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343) - Neoplasms | Phase 1 | Completed | Bayer | 173 | 2017-05-26 | 2022-06-30 |
| Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies palifosfamide-tris - Malignancy, Cancer | Phase 1 | Completed | Alaunos Therapeutics | 22 | 2010-12-01 | 2026-09-29 |
| Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies Esophageal sparing IMRT - Non Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 1 | Completed | Duke University | 24 | 2009-09-11 | 2020-04-02 |
| Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma Gleevec (imatinib) - Thymic Carcinoma | Phase 1 | Completed | Indiana University | 11 | 2006-04-01 | 2014-06-03 |
| Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions recombinant adenovirus-hIFN-beta - Cancer | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 2003-04-01 | 2020-05-13 | |
| MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma entinostat - Cancer | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 75 | 2001-03-01 | 2012-03-15 |
Carcinoma, Non-Small-Cell Lung (8) · Small Cell Lung Carcinoma (6) · Neoplasms (5) · Uterine Cervical Neoplasms (5) · Breast Neoplasms (4) · Melanoma (4) · Ovarian Neoplasms (4) · Pancreatic Neoplasms (4) · Prostatic Neoplasms (4) · Stomach Neoplasms (4) · Urinary Bladder Neoplasms (4) · Anus Neoplasms (3) · Bile Duct Neoplasms (3) · Carcinoma, Hepatocellular (3)
Hemic and Lymphatic Diseases (11) · Lymphatic Diseases (11) · Neoplasms by Histologic Type (11) · Neoplasms by Site (11) · Neoplasms, Complex and Mixed (11) · Thoracic Neoplasms (11) · Lung Diseases (9) · Respiratory Tract Diseases (9) · Respiratory Tract Neoplasms (9) · Bronchial Neoplasms (8) · Carcinoma, Bronchogenic (8) · Lung Neoplasms (8) · Thymus Neoplasms (8) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7)
Cisplatin (1) · Gemcitabine (1) · Imatinib Mesylate (1) · Nivolumab (1) · Pemetrexed (1) · anetumab ravtansine (1) · bosutinib (1) · entinostat (1) · isophosphamide mustard (1) · olaparib (1) · vorolanib (1)
Abramson Cancer Center at Penn Medicine (1) · Alaunos Therapeutics (1) · Bayer (1) · Duke University (1) · Indiana University (1) · Nagla Abdel Karim (1) · National Institutes of Health Clinical Center (CC) (1) · Quadriga Biosciences, Inc. (1) · Vanderbilt-Ingram Cancer Center (1) · Vastra Gotaland Region (1) · Xencor, Inc. (1)
United States (9) · Australia (2) · Belgium (1) · Canada (1) · France (1) · Italy (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Christopher Kelsey, MD (1) · Daniel H. Sterman, MD (1) · Kathryn Beckermann, MD (1) · Nagla Karim, MD (1) · Patrick Loehrer (1) · Shivaani Kummar, MD (1) · Zequn Tang, MD (1)
PMID 20068553, PMID 34114913, PMID 34829796
2016 (1), 2019 (1)